Till now all best possible costly medicines to treat cancers,HIV,Hepatitis B,C,influenza,spine flue or fungal infections are available as cheap in India as many US suppliers supply it to third world countries in cheap rate but as quality and sale is more stringent in USA so USA was not accepting drugs manufactured in other countries and even for quality and to earn profit they keep price of such drugs very costly in their country so there is hugh balckmarketing as these drugs ar purchased in third world countries and the resupplied to USA.

             But now,in a move that drew cautious responses from oncology groups and patient advocates, President Donald Trump announced a sweeping “blueprint” to lower prescription drug costs, promising to expand access to generic drugs and biosimilars and remove incentives that keep drug prices high.The move includes an FDA evaluation of whether drug manufacturers should be required to list prices in their advertising, as well as longer-term efforts to change the imbalance between what US consumers pay for drugs developed in the United States versus what foreigners pay in their own countries, where drug prices are often substantially lower.

                Other proposed changes included activating programs that enable CMS to stimulate drug price negotiation among Medicare Part D plan sponsors and improve the value of drug purchasing programs. “We will have tougher negotiation, more competition, and much lower prices at the pharmacy counter,” Trump said in a Rose Garden speech.

              The Community Oncology Alliance (COA) issued a statement saying that it “strongly supports” efforts to reduce drug prices. However, the organization criticized the administration because the plan leaves in place a 2% sequester cut made to Medicare reimbursement for cancer drugs in 2013.

             “Today, President Trump has proposed several important initiatives to lower drug prices that align perfectly with COA’s ongoing work to advance meaningful, patient-centered solutions aimed at making cancer care less costly and more effective,” said executive director Ted Okon. “However, it is really disturbing that the blueprint released today does not address the Medicare sequester cut to drug payments that is fueling higher costs and cancer drug prices. All the sequester cut to Medicare drug payments for cancer drugs has produced is less access to cancer treatment, higher costs for patients and Medicare, and increased drug prices. It has to be stopped now.”